Diabetes and the Gut Microbiome

Semin Nephrol. 2021 Mar;41(2):104-113. doi: 10.1016/j.semnephrol.2021.03.005.

Abstract

Gut dysbiosis in diabetes mellitus is associated with decreased short-chain fatty acids and epithelial barrier disruption. Microbial-derived toxins move across the "leaky gut" and incur systemic inflammation and insulin resistance. In children, gut dysbiosis has been associated with risk of developing type 1 diabetes mellitus. In animal models, the obesity phenotype is transferable via microbiota transplantation. Plant-based low protein diets and certain anti-diabetic drugs have been associated with positive microbiome effects. Clinical trials with prebiotics and probiotics have yielded mixed results. Further investigations are needed to evaluate the gut microbiome as a potential therapeutic target for diabetes prevention and management.

Keywords: Diabetes mellitus; gut microbiome; prebiotics; probiotics.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2*
  • Dysbiosis
  • Gastrointestinal Microbiome*
  • Humans
  • Prebiotics
  • Probiotics* / therapeutic use

Substances

  • Prebiotics